相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1987
已完成
4
80.0%
Unknown
1
20.0%
暂无批准数据
- The first clinical trial exclusively focused on pre-extensively drug-resistant tuberculosis (pre-XDR-TB) shows that shorter treatment regimens benefit some patients but not all. - The experimental six-to-nine-month regimen achieved 87% effectiveness compared to 89% for standard 18-24 month therapy, but failed to meet non-inferiority standards across the full study population. - Patients with advanced lung damage did not respond as well to shorter treatment, highlighting the need for individualized therapy based on disease severity and resistance patterns. - Researchers call for updated WHO guidelines to incorporate stratified treatment approaches rather than universal six-month regimens for all patients with drug-resistant TB.
- A phase 3 clinical trial, endTB, has identified three new 9-month, all-oral drug regimens as effective alternatives to the standard 18-24 month treatment for rifampin-resistant tuberculosis. - The new regimens, combining drugs like bedaquiline and delamanid, demonstrated favorable outcomes in 85% to 90% of participants, comparable to the 81% success rate of the control group. - These shorter, less toxic regimens have been endorsed by the WHO and offer improved accessibility and affordability, with some costing less than $500, potentially transforming TB treatment. - The study included diverse populations, such as children, pregnant women, and individuals with HIV or hepatitis C, often excluded from clinical trials, making the findings broadly applicable.
